Development and bioavailability improvement of Resiquimod in the form of solid lipid nanoparticles

Abstract

The present study aims to develop Resiquimod's Solid Lipid Nanoparticles (SLNs) for topical drug delivery. To evaluate the physicochemical characterization of Resiquimod, lipids, polymers, surfactants & other additives. Formulation & Evaluation of SLNs for particle size analysis, Zeta potential, entrapment efficiency, polydispersity index (PDI), and % yield of produced SLNs. Based on the current studies, it can be said that Resiquimod solid lipid nanoparticles were effectively created and optimized. Hydrogels of prepared SLNs can be applied topically to treat skin conditions such as actinic keratoses (AKs). Different concentrations of lipids and surfactants were used to design SLNs. Mannitol showed much effectiveness as a Cryoprotectant. The drug's excipient Research on the compatibility of drugs, lipids, polymers, and their combinations using FTIR and DSC confirms that the drugs and excipients do not interact chemically. The Nanoparticles in the SLN droplets were intact, non-aggregated, and almost spherical according to scanning electron microscopy (SEM) pictures. The particle size of SLNs loaded with Resiquimod ranges from 208 to 503 nm. This could contribute to the SLNs' more extended blood circulation period. It was discovered that the PDI was less than 0.6. Adequate stability was demonstrated by the negative charge of the zeta potential in the formulation of SLNs. The results are encouraging and represent a novel contribution of Resiquimod SLNs in Topical Drug Delivery.